 Doses of 10 mgday prednisone or equivalent should not be exceeded during the study Exclusion Criteria: - ACR functional class IV or ARA anatomical stage IV - Subjects that are scheduled for surgery or being evaluated for surgery for hands, wrist and feet - Feltys syndrome - Any poorly controlled, clinically significant systemic disease e.g., chronic obstructive pulmonary disease, congestive heart failure, stroke, chronic renal failure, liver disease - Poorly controlled diabetes mellitus e.g., diabetics with HbA1C greater than 8, peripheral neuropathy, renalretinal involvement, or vascular disorders - Malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the past 5 years - Abnormal chest x-ray that is clinically significant or bronchiectasis - Within 12 weeks before date of enrollment any of the following occurrences: presence of serious infection e.g., requiring hospitalization andor IV antibiotics, frequent, acute, or chronic infections - History of chronic infection - Recent history within 24 weeks of enrollment of drug or alcohol abuse - Known to be positive for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus - Presence of any condition that may compromise the ability of the subject to give informed consent - Planned events e.g., planned hospitalizations, vacations, etc. that would interfere with the collection of the required assessments andor may prevent the subject from completing the study according to protocol - White cell count less than or equal to 3.5 x 109L, a neutrophil count of less than or equal to 2.5 x 109L, or platelet count of less than or equal to 125 x 109L at screening - Hemoglobin less than or equal to 8.0 gdL at screening - Elevated AST or ALT greater than or equal to 1.5 x the upper limit of normal at screening - Elevated serum creatinine greater than or equal to 1.5 x the upper limit of normal at screening - Received intra-articular or systemic corticosteroid injections within 4 weeks before enrollment - Subjects who have received previous treatment with anti-IL-1ra or anti-TNF therapies e.g., anakinra, etanercept or infliximab within 4 weeks prior to enrollment - Subjects who are pregnant or breast-feeding, or plan to become pregnant during the course of the study - Subject man or woman is of child bearing potential and not using adequate contraceptive precautions - Known allergy to E. coli derived products - Receiving or has received any investigational drug within the previous 30 days or within 5 half-lives of any investigational drug, whichever is greater or is currently using an investigational device 